Special Issue

Adamantane in Drug Delivery

Message from the Guest Editor

Nanomedicine offers a new platform for drug delivery development. Great progress has been made in the field of cancer nanomedicine, regenerative medicine, immunotherapy, gene delivery and bioimaging. The unique structural and chemical properties of adamantane provide exceptional opportunities in the design of various adamantane-based scaffolds or carrier systems for drug delivery. Adamantane can be used in two ways; as a building block to which different functional groups are covalently bonded or as part of self-assembled supramolecular systems where adamantane is accommodated on the basis of its lipophilicity and strong host–guest interaction. Due to its lipophilicity, adamantane attachment to drugs with low hydrophobicity could increase the drug uptake through the lipidic membranes. Additional important features of adamantane are its biocompatibility and non-toxicity, as well as its low cost and easy accessibility. Nanomaterials containing adamantane and other diamondoids therefore remain highly relevant to nanomedicine, especially in the design of safe and selective drug delivery systems and molecular carriers.

Guest Editor

Prof. Dr. Ruža Frkanec

Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, 10000 Zagreb, Croatia

Deadline for manuscript submissions

closed (31 October 2022)

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/si/102877

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/pharmaceutics

MDPI

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).